Provided by Tiger Trade Technology Pte. Ltd.

Sarepta Therapeutics

17.50
-0.0700-0.40%
Post-market: 17.500.00000.00%19:59 EDT
Volume:2.55M
Turnover:44.42M
Market Cap:1.85B
PE:-13.30
High:17.76
Open:17.75
Low:17.21
Close:17.57
52wk High:25.32
52wk Low:14.68
Shares:105.57M
Float Shares:99.05M
Volume Ratio:1.19
T/O Rate:2.57%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3161
EPS(LYR):-7.1300
ROE:-9.48%
ROA:-1.13%
PB:1.21
PE(LYR):-2.45

Loading ...

Sarepta Grants New CEO Severino Options for 2,224,342 Shares at $17.74, Plus 756,104 RSUs

Reuters
·
Jul 30

Sarepta Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jul 30

FDA Advisers Vote Against Capricor's Duchenne Heart Disease Therapy

Reuters
·
Jul 30

Earning Preview: Sarepta Therapeutics Q2 revenue is expected to decrease by 31.25%, and institutional views are mixed leaning bullish

Earnings Agent
·
Jul 30

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Vericel (VCEL), Sarepta Therapeutics (SRPT) and Neumora Therapeutics, Inc. (NMRA)

TIPRANKS
·
Jul 28

Morgan Stanley says Sarepta’s CEO transition brings clarity ahead of catalysts

TIPRANKS
·
Jul 27

Sarepta Gains After Appointing Former AbbVie Executive Severino as CEO

Reuters
·
Jul 27

Sarepta Names Michael Severino CEO, Succeeding Retiring Doug Ingram

Reuters
·
Jul 27

Sarepta Therapeutics - Doug Ingram to Retire and Serve as Advisor Until End of 2026

THOMSON REUTERS
·
Jul 27

Sarepta Therapeutics Appoints Michael Severino, M.d., Chief Executive Officer

THOMSON REUTERS
·
Jul 27

Press Release: Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results

Dow Jones
·
Jul 22

Analysts Offer Insights on Healthcare Companies: Compugen (CGEN), Telix Pharmaceuticals (OtherTLPPF) and Sarepta Therapeutics (SRPT)

TIPRANKS
·
Jul 22

Has Sarepta Therapeutics (SRPT) Fallen Below Fair Value After FDA Progress?

Simply Wall St.
·
Jul 19

Is Sarepta Therapeutics (SRPT) Undervalued Following FDA Progress On AMONDYS 45 And VYONDYS 53?

Simply Wall St.
·
Jul 15

Analysts Offer Insights on Healthcare Companies: Forte Biosciences (FBRX), Sarepta Therapeutics (SRPT) and Opus Genetics (IRD)

TIPRANKS
·
Jul 10

Sarepta Therapeutics Raised to Outperform from Peer Perform by Wolfe Research

Dow Jones
·
Jul 09

Sarepta price target lowered to $20 from $23 at Piper Sandler

TIPRANKS
·
Jul 09

Sarepta upgraded to Outperform from Peer Perform at Wolfe Research

TIPRANKS
·
Jul 09

Why Sarepta Therapeutics (SRPT) Is Up 12.7% After FDA Accepts sNDAs Backed By ESSENCE Data

Simply Wall St.
·
Jul 08

H.C. Wainwright says Sarepta news does not signal full approvals

TIPRANKS
·
Jul 01